SPOP-mediated degradation of BRD4 dictates cellular sensitivity to BET inhibitors

References

• Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18:246–62. doi:10.1038/nrm.2016.143. PMID:28053347
   PubMed Web of Science ®Google Scholar
• Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell. 2013;154:569–82. doi:10.1016/j.cell.2013.07.013. PMID:23911322
   PubMed Web of Science ®Google Scholar
• Fu LL, Tian M, Li X, Li JJ, Huang J, Ouyang L, Zhang Y, Liu B. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 2015;6:5501–16. doi:10.18632/oncotarget.3551. PMID:25849938
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13:337–56. doi:10.1038/nrd4286. PMID:24751816
   PubMed Web of Science ®Google Scholar
• Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12:465–77. doi:10.1038/nrc3256. PMID:22722403
   PubMed Web of Science ®Google Scholar
• Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54:728–36. doi:10.1016/j.molcel.2014.05.016. PMID:24905006
   PubMed Web of Science ®Google Scholar
• Zeng L, Zhou MM. Bromodomain: an acetyl-lysine binding domain. FEBS Lett. 2002;513:124–8. doi:10.1016/S0014-5793(01)03309-9. PMID:11911891
   PubMed Web of Science ®Google Scholar
• Wu SY, Chiang CM. The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation. J Biol Chem. 2007;282:13141–5. doi:10.1074/jbc.R700001200. PMID:17329240
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. The bromodomain interaction module. FEBS Lett. 2012;586:2692–704. doi:10.1016/j.febslet.2012.04.045. PMID:22710155
   PubMed Web of Science ®Google Scholar
• Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MG, Qi J, Rahl PB, Sun HH, Yeda KT, Doench JG, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777–90. doi:10.1016/j.ccr.2013.11.003. PMID:24332044
   PubMed Web of Science ®Google Scholar
• Pott S, Lieb JD. What are super-enhancers? Nat Genet. 2015;47:8–12. doi:10.1038/ng.3167. PMID:25547603
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17. doi:10.1016/j.cell.2011.08.017. PMID:21889194
   PubMed Web of Science ®Google Scholar
• Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, et al. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature. 2014;510:278–82. doi:10.1038/nature13229. PMID:24759320
   PubMed Web of Science ®Google Scholar
• Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19:523–34. doi:10.1016/j.molcel.2005.06.027. PMID:16109376
   PubMed Web of Science ®Google Scholar
• Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19:535–45. doi:10.1016/j.molcel.2005.06.029. PMID:16109377
   PubMed Web of Science ®Google Scholar
• French CA, Miyoshi I, Kubonishi I, Grier HE, Perez-Atayde AR, Fletcher JA. BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. Cancer Res. 2003;63:304–7. PMID:12543779
   PubMed Web of Science ®Google Scholar
• Crawford NP, Alsarraj J, Lukes L, Walker RC, Officewala JS, Yang HH, Lee MP, Ozato K, Hunter KW. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci U S A. 2008;105:6380–5. doi:10.1073/pnas.0710331105. PMID:18427120
   PubMed Web of Science ®Google Scholar
• Klein K, Kabala PA, Grabiec AM, Gay RE, Kolling C, Lin LL, Gay S, Tak PP, Prinjha RK, Ospelt C, et al. The bromodomain protein inhibitor I-BET151 suppresses expression of inflammatory genes and matrix degrading enzymes in rheumatoid arthritis synovial fibroblasts. Ann Rheum Dis. 2016;75:422–9. doi:10.1136/annrheumdis-2014-205809. PMID:25467295
   PubMed Web of Science ®Google Scholar
• Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, et al. BET bromodomain proteins are required for glioblastoma cell proliferation. Epigenetics. 2014;9:611–20. doi:10.4161/epi.27906. PMID:24496381
   PubMed Web of Science ®Google Scholar
• Wu SY, Lee AY, Lai HT, Zhang H, Chiang CM. Phospho switch triggers Brd4 chromatin binding and activator recruitment for gene-specific targeting. Mol Cell. 2013;49:843–57. doi:10.1016/j.molcel.2012.12.006. PMID:23317504
   PubMed Web of Science ®Google Scholar
• Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, et al. An epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014;24:809–19. doi:10.1038/cr.2014.71. PMID:24874954
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–8. doi:10.1038/nature10334. PMID:21814200
   PubMed Web of Science ®Google Scholar
• Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clin Cancer Res. 2014;20:912–25. doi:10.1158/1078-0432.CCR-13-2281. PMID:24297863
   PubMed Web of Science ®Google Scholar
• Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, et al. Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. Nature. 2016;529:413–7. doi:10.1038/nature16508. PMID:26735014
   PubMed Web of Science ®Google Scholar
• De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H, et al. PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature. 2014;514:247–51. PMID:25119042
   PubMed Web of Science ®Google Scholar
• Rathert P, Roth M, Neumann T, Muerdter F, Roe JS, Muhar M, Deswal S, Cerny-Reiterer S, Peter B, Jude J, et al. Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature. 2015;525:543–7. doi:10.1038/nature14898. PMID:26367798
   PubMed Web of Science ®Google Scholar
• Fong CY, Gilan O, Lam EY, Rubin AF, Ftouni S, Tyler D, Stanley K, Sinha D, Yeh P, Morison J, et al. BET inhibitor resistance emerges from leukaemia stem cells. Nature. 2015;525:538–42. doi:10.1038/nature14888. PMID:26367796
   PubMed Web of Science ®Google Scholar
• Dai X, Gan W, Li X, Wang S, Zhang W, Huang L, Liu S, Zhong Q, Guo J, Zhang J, et al. Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med. 2017;23:1063–71. doi:10.1038/nm.4378.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang D, Zhao Y, Ren S, Gao K, Ye Z, Wang S, Pan CW, Zhu Y, Yan Y, et al. Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT-mTORC1 activation. Nat Med. 2017;23:1055–62. doi:10.1038/nm.4379.
   PubMed Web of Science ®Google Scholar
• Mani RS. The emerging role of speckle-type POZ protein (SPOP) in cancer development. Drug Discov Today. 2014;19:1498–502. doi:10.1016/j.drudis.2014.07.009. PMID:25058385
   PubMed Web of Science ®Google Scholar
• Gan W, Dai X, Lunardi A, Li Z, Inuzuka H, Liu P, Varmeh S, Zhang J, Cheng L, Sun Y, et al. SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell. 2015;59:917–30. doi:10.1016/j.molcel.2015.07.026. PMID:26344095
   PubMed Web of Science ®Google Scholar
• An J, Ren S, Murphy SJ, Dalangood S, Chang C, Pang X, Cui Y, Wang L, Pan Y, Zhang X, et al. Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. Mol Cell. 2015;59:904–16. doi:10.1016/j.molcel.2015.07.025. PMID:26344096
   PubMed Web of Science ®Google Scholar
• An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep. 2014;6:657–69. doi:10.1016/j.celrep.2014.01.013. PMID:24508459
   PubMed Web of Science ®Google Scholar
• Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D, O'Malley BW. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene. 2011;30:4350–64. doi:10.1038/onc.2011.151. PMID:21577200
   PubMed Web of Science ®Google Scholar
• Theurillat JP, Udeshi ND, Errington WJ, Svinkina T, Baca SC, Pop M, Wild PJ, Blattner M, Groner AC, Rubin MA, et al. Prostate cancer. Ubiquitylome analysis identifies dysregulation of effector substrates in SPOP-mutant prostate cancer. Science. 2014;346:85–9. doi:10.1126/science.1250255. PMID:25278611
   PubMed Web of Science ®Google Scholar
• Zhu H, Ren S, Bitler BG, Aird KM, Tu Z, Skordalakes E, Zhu Y, Yan J, Sun Y, Zhang R. SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. Cell Rep. 2015;13:1183–93. doi:10.1016/j.celrep.2015.09.083. PMID:26527005
   PubMed Web of Science ®Google Scholar
• Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ, Price JC, Zhang S, England BM, Godwin AK, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310–5. doi:10.1038/ng.2455. PMID:23104009
   PubMed Web of Science ®Google Scholar
• Zhang P, Gao K, Jin X, Ma J, Peng J, Wumaier R, Tang Y, Zhang Y, An J, Yan Q, et al. Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-alpha protein turnover. Cell Death Dis. 2015;6:e1687. doi:10.1038/cddis.2015.47. PMID:25766326
   PubMed Web of Science ®Google Scholar
• Guo ZQ, Zheng T, Chen B, Luo C, Ouyang S, Gong S, Li J, Mao LL, Lian F, Yang Y, et al. Small-Molecule Targeting of E3 Ligase Adaptor SPOP in Kidney Cancer. Cancer Cell. 2016;30:474–84. doi:10.1016/j.ccell.2016.08.003. PMID:27622336
   PubMed Web of Science ®Google Scholar
• Li G, Ci W, Karmakar S, Chen K, Dhar R, Fan Z, Guo Z, Zhang J, Ke Y, Wang L, et al. SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. Cancer Cell. 2014;25:455–68. doi:10.1016/j.ccr.2014.02.007. PMID:24656772
   PubMed Web of Science ®Google Scholar
• Kim B, Nam HJ, Pyo KE, Jang MJ, Kim IS, Kim D, Boo K, Lee SH, Yoon JB, Baek SH, et al. Breast cancer metastasis suppressor 1 (BRMS1) is destabilized by the Cul3-SPOP E3 ubiquitin ligase complex. Biochem Biophys Res Commun. 2011;415:720–6. doi:10.1016/j.bbrc.2011.10.154. PMID:22085717
   PubMed Web of Science ®Google Scholar
• Janouskova H, El Tekle G, Bellini E, Udeshi ND, Rinaldi A, Ulbricht A, Bernasocchi T, Civenni G, Losa M, Svinkina T, et al. Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. Nat Med. 2017;23:1046–54. doi:10.1038/nm.4372. PMID:28805821
   PubMed Web of Science ®Google Scholar